Global Migraine Drugs Market - 2019-2026
発行: DataM Intelligence
片頭痛はおそらく神経学における障害の最も一般的な原因です。近年、片頭痛の症例が大幅に増加しています。たとえば、2015年の国立バイオテクノロジー情報センターによると、片頭痛は、人生のある時点で20％以上の人々に影響を与えているとされています。疫学調査によると、西欧の人口のほぼ4.5％が少なくとも月に15日間頭痛を抱えています。研究によれば、片頭痛はまた、 米国で3,100万人以上の人々に影響を及ぼし、 米国で 3番目に一般的な疾患であり、おそらく2番目の主要な障害の原因でさえあります。したがって、片頭痛治療の急増は、市場成長の主要な要因であると予想されます。さらに、体に有害な製品の使用の増加と慢性疾患の有病率の増加は、片頭痛薬の需要の高まりの主な要因となっています。
Migraine is a condition of the neurology which can cause multiple symptoms. It is marked often by severe and debilitating headaches. Symptoms can include nausea, vomiting, difficulty speaking, numbness or tingling, and others. Migraines occur inside families and influence all ages. Diagnosis of migraine headaches is assessed from clinical history and reported symptoms. Migraines may arise in infancy or may not appear until early adulthood. Females are more prone to experience migraines than men. Genetic background is one of the most common sign factors for migraines. Symptoms of migraines will start one to two days before the headache itself. This is classified as a stage of the prodrome. Migraine pain more often impacts the area of the forehead. It's normally on one side of the head, but on both sides, it may occur. The Migraine Drugs market valued USDXX million in 2018 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2026.
Migraine is perhaps the most common cause of disability in neurology. There has been a substantial increase in migraine cases in recent years. For instance, in 2015, As per the National Center for Biotechnology Information, migraine impacts more than 20 percent of people at some point in their lives in 2015; epidemiological studies have shown that almost 4.5 percent of Western Europe's population has a headache on at least 15 days a month. As per the study, migraine also affects upwards of 31 million people in the United States and is the third most common disease and perhaps even the second leading cause of disability worldwide. Thus, a surge in migraine medications is expected to be a key factor in market growth. In addition, the growing use of unhealthy products and the increasing prevalence of chronic disease are the main factors responsible for the rise of the demand for migraine drugs.
Side effects associated with migraine drugs may act as restrain for market growth. However, there is growing demand emerging market, due to rising disposal income and increasing numbers of migraine patients are expected to present a wide range of growth opportunities for market players.
Global migraine drugs are segmented into treatment type, route of administration, and distribution channel. Based on the treatment type, the market is segmented into prophylactic and abortive. On the basis of route of administration, the market is segmented into injectable, oral, and others. Based in distribution channel, the global migraine drugs market is diversified as hospital pharmacies, retail pharmacies, and others.
Currently, there are three novel drugs in late-stage pipeline that are set to change the treatment landscape. These drugs follow disease-modifying approaches and are associated with superior clinical efficacy and a favorable safety profile compared to currently marketed drugs.
Allergan's ubrogepant and Eli Lilly's Lasmiditan are expected to be first-in-class migraine drugs with novel mechanism of actions for patients unresponsive to triptans or those who are at risk of cardiovascular disorders.Several triptans under late-stage development consist of reformulation of generic triptans, with an aim to improve the efficacy of existing formulations. Zosano Pharma's M207 is being investigated in Phase III ADAM (NCT03282227) trial. The drug is a novel formulation of zolmitriptan delivered via Zosano's proprietary Adhesive Dermally-Applied Microarray (ADAM) technology.
By region, the Migraine Drugs market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the Migraine Drugs market due to the high usage of the Migraine Drugs. Additionally, Migraine is the third most prevalent and the sixth most disabling illness in the world, affecting more than 37 million in the U.S. and over one billion people worldwide. United States dominated the market with more than 65% share in 2017 and is projected to maintain its position until 2025. Launch of CGRP based therapies, high prevalence, increasing adoption of novel therapeutics, and a large target population in the U.S. is some of the factors contributing to the dominance of the country
Key players operating in the market are Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, and others. Leading multinational players dominate the market and hold substantial market share, thereby, presenting tough competition to new entrants. Key players focus on various strategic initiatives such as merger & acquisition, geographical expansion, new product launch and increasing R&D expenditure to stay competitive in the market. For instance, in 2019 Allergen Company announced that a New Drug Application for UBRELVY for the acute treatment of migraines with or without aura in adults. This drug was approved by the Food and Drug Administration (United States). This acquisition will affect the growth of the market in the future.
Until 2017, Allergan's Botox, a neurotoxin was in a strong competitive position in the preventive migraine market. As the only drug approved for prevention, Botox commanded premium pricing with more than 60.0% market share in 2017. However, Botox is expected to face competition from launch of Amgen/Novartis' Aimovig and other highly efficacious CGRP-based therapies, which target both chronic and episodic migraine, as opposed to Botox, which is only approved for the chronic variant of the condition.